Chargement en cours...
Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling
After Taxotere fails, treatment options for metastatic prostate cancer are limited. The three drugs with FDA approval in this setting, Jevtana, Provenge and Zytiga, are associated with median survivals of less than 2 years. In part, the impact on survival is the result of low response rates, indicat...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
S. Karger AG
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3364088/ https://ncbi.nlm.nih.gov/pubmed/22666205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000338077 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|